3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
2
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
2
Thoracic
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Melanoma
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
pembrolizumab
81
Nivolumab
55
Ipilimumab
44
Cyclophosphamide
37
aldesleukin
26
Interleukin-2
25
Temozolomide
17
fludarabine
16
fludarabine phosphate
15
trametinib
11
dabrafenib
11
Radiotherapy
11
Biopsy
11
avelumab
10
Paclitaxel
9
spartalizumab
8
cemiplimab
8
Dacarbazine
8
Cisplatin
8
Bevacizumab
8
sargramostim
7
binimetinib
7
Fluorouracil
7
poly ICLC
6
lenvatinib
6
epacadostat
6
atezolizumab
6
Magnetic Resonance Spectroscopy
6
Granulocyte-Macrophage Colony-Stimulating Factor
6
montanide ISA 51
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
utomilumab
×
Dermatologic
×
Clear all
NCT02554812
2024-07-30
JAVELIN Medley
Pfizer
Phase 1/2
Terminated
409 enrolled
108 charts